The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond
Open accessAbstract
CXCR3 is a chemokine receptor with three ligands; CXCL9, CXCL10, and CXCL11. CXCL11 binds CXCR3 with a higher affinity than the other ligands leading to receptor internalization. Long ago we reported that one of these chemokines, CXCL10, not only attracts CXCR3+ CD4+ and CD8+ effector T cells to sites of inflammation, but also direct their polarization into highly potent effector T cells. Later we showed that CXCL11 directs the linage development of T-regulatory-1 cells (Tr1). We also observed that CXCL11 and CXCL10 induce different signaling cascades via CXCR3. Collectively this suggests that CXCR3 ligands differentially regulate the biological function of T cells via biased signaling. It is generally accepted that tumor cells evolved to express several chemokine receptors and secrete their ligands. Vast majority of these chemokines support tumor growth by different mechanisms that are discussed. We suggest that CXCL10 and possibly CXCL9 differ from other chemokines by their ability to restrain tumor growth and enhance anti-tumor immunity. Along with this an accumulating number of studies showed in various human cancers a clear association between poor prognosis and low expression of CXCL10 at tumor sites, and vice versa. Finally, we discuss the possibility that CXCL9 and CXCL10 may differ in their biological function via biased signaling and its possible relevance to cancer immunotherapy. The current mini review focuses on exploring the role of CXCR3 ligands in directing the biological properties of CD4+ and CD8+ T cells in the context of cancer and autoimmunity. We believe that the combined role of these chemokines in attracting T cells and also directing their biological properties makes them key drivers of immune function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Functional diversity of helper T lymphocytes
Abbas, A. K., Murphy, K. M., & Sher, A. (1996) · Nature · doi:10.1038/383787a0 · Cited by 4,450
Chemokines — Chemotactic Cytokines That Mediate Inflammation
Luster, A. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380706 · Cited by 3,630
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
The role of myeloid cells in the promotion of tumour angiogenesis
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642
β-Arrestin-Dependent Formation of β 2 Adrenergic Receptor-Src Protein Kinase Complexes
Luttrell, L. M., Ferguson, S. S. G., Daaka, Y., Miller, W. E., Maudsley, S., Della Rocca, G. J., Lin, F.-T., Kawakatsu, H., Owada, K., Luttrell, D. K., et al. (1999) · Science · doi:10.1126/science.283.5402.655 · Cited by 1,475
Samama, P., Cotecchia, S., Costa, T., & Lefkowitz, R. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53442-6 · Cited by 1,257
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121
Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL
Staller, P., Sulitkova, J., Lisztwan, J., Moch, H., Oakeley, E. J., & Krek, W. (2003) · Nature · doi:10.1038/nature01874 · Cited by 870 · cited 2×
“Chemokine receptor -chemokine axis Key pathways References CCR2-CCL2 Direct support of tumor growth, recruitment of tumor associated macrophages (TAMs) to support tumor growth and suppress anti-tumor immune reactivity (52–56) CXCR4-CXCL12 Direct support of tumor growth, metastatic spread, particularly to the bones (48…”
BackgroundCole, K. E., Strick, C. A., Paradis, T. J., Ogborne, K. T., Loetscher, M., Gladue, R. P., Lin, W., Boyd, J. G., Moser, B., Wood, D. E., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.12.2009 · Cited by 870
Chow, M. T., Ozga, A. J., Servis, R. L., Frederick, D. T., Lo, J. A., Fisher, D. E., Freeman, G. J., Boland, G. M., & Luster, A. D. (2019) · Immunity · doi:10.1016/j.immuni.2019.04.010 · Cited by 716 · cited 1×
“Only recently it has been suggested that that CXCL9 is also involved in directing the potentiation of CD8+ T cells in cancer, and that its activity differs from CCL10 (7).”
BackgroundBiased Signaling Pathways in β 2 -Adrenergic Receptor Characterized by 19 F-NMR
Liu, J. J., Horst, R., Katritch, V., Stevens, R. C., & Wüthrich, K. (2012) · Science · doi:10.1126/science.1215802 · Cited by 697
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
Plitas, G., Konopacki, C., Wu, K., Bos, P. D., Morrow, M., Putintseva, E. V., Chudakov, D. M., & Rudensky, A. Y. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.032 · Cited by 695
Biochemical characterization of a gamma interferon-inducible cytokine (IP-10).
Luster, A. D., & Ravetch, J. V. (1987) · The Journal of experimental medicine · doi:10.1084/jem.166.4.1084 · Cited by 666
Sierro, F., Biben, C., Martínez-Muñoz, L., Mellado, M., Ransohoff, R. M., Li, M., Woehl, B., Leung, H., Groom, J., Batten, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702229104 · Cited by 624
Ganju, R. K., Brubaker, S. A., Meyer, J., Dutt, P., Yang, Y., Qin, S., Newman, W., & Groopman, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.36.23169 · Cited by 613
Molecular Mechanism of β-Arrestin-Biased Agonism at Seven-Transmembrane Receptors
Reiter, E., Ahn, S., Shukla, A. K., & Lefkowitz, R. J. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105800 · Cited by 583
Homeostatic chemokine receptors and organ-specific metastasis
Zlotnik, A., Burkhardt, A. M., & Homey, B. (2011) · Nature Reviews Immunology · doi:10.1038/nri3049 · Cited by 571
Mikucki, M. E., Fisher, D. T., Matsuzaki, J., Skitzki, J. J., Gaulin, N. B., Muhitch, J. B., Ku, A. W., Frelinger, J. G., Odunsi, K., Gajewski, T. F., et al. (2015) · Nature Communications · doi:10.1038/ncomms8458 · Cited by 512
Halama, N., Zoernig, I., Berthel, A., Kahlert, C., Klupp, F., Suarez-Carmona, M., Suetterlin, T., Brand, K., Krauss, J., Lasitschka, F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.005 · Cited by 495
IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo.
Luster, A. D., & Leder, P. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.3.1057 · Cited by 407
Chemokines: agents for the immunotherapy of cancer?
Homey, B., Müller, A., & Zlotnik, A. (2002) · Nature Reviews Immunology · doi:10.1038/nri748 · Cited by 398
Barreira da Silva, R., Laird, M. E., Yatim, N., Fiette, L., Ingersoll, M. A., & Albert, M. L. (2015) · Nature Immunology · doi:10.1038/ni.3201 · Cited by 337
Loberg, R. D., Ying, C., Craig, M., Day, L. L., Sargent, E., Neeley, C., Wojno, K., Snyder, L. A., Yan, L., & Pienta, K. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1286 · Cited by 333
CCL2 (monocyte chemoattractant protein-1) and cancer
Conti, I., & Rollins, B. J. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.10.009 · Cited by 314
Mechanisms of cancer dissemination along nerves
Amit, M., Na'ara, S., & Gil, Z. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.38 · Cited by 308
β cells are responsible for CXCR3-mediated T-cell infiltration in insulitis
Frigerio, S., Junt, T., Lu, B., Gerard, C., Zumsteg, U., Holländer, G. A., & Piali, L. (2002) · Nature Medicine · doi:10.1038/nm1202-792 · Cited by 301
Müller, M., Carter, S., Hofer, M. J., & Campbell, I. L. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01089.x · Cited by 293
CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells
Velasco-Velázquez, M., Jiao, X., De La Fuente, M., Pestell, T. G., Ertel, A., Lisanti, M. P., & Pestell, R. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3917 · Cited by 282
Fife, B. T., Kennedy, K. J., Paniagua, M. C., Lukacs, N. W., Kunkel, S. L., Luster, A. D., & Karpus, W. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7617 · Cited by 256
CCR8+FOXp3+Tregcells as master drivers of immune regulation
Barsheshet, Y., Wildbaum, G., Levy, E., Vitenshtein, A., Akinseye, C., Griggs, J., Lira, S. A., & Karin, N. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621280114 · Cited by 249
Self-citationChemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity
Karin, N., & Razon, H. (2018) · Cytokine · doi:10.1016/j.cyto.2018.02.012 · Cited by 222
Self-citationMüller, M., Carter, S. L., Hofer, M. J., Manders, P., Getts, D. R., Getts, M. T., Dreykluft, A., Lu, B., Gerard, C., King, N. J. C., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.2774 · Cited by 198
Yellin, M., Paliienko, I., Balanescu, A., Ter‐Vartanian, S., Tseluyko, V., Xu, L., Tao, X., Cardarelli, P. M., LeBlanc, H., Nichol, G., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34330 · Cited by 194
Wennerberg, E., Kremer, V., Childs, R., & Lundqvist, A. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1629-5 · Cited by 192
Zohar, Y., Wildbaum, G., Novak, R., Salzman, A. L., Thelen, M., Alon, R., Barsheshet, Y., Karp, C. L., & Karin, N. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71951 · Cited by 184
Self-citationCCR5+ Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions
Blattner, C., Fleming, V., Weber, R., Himmelhan, B., Altevogt, P., Gebhardt, C., Schulze, T. J., Razon, H., Hawila, E., Wildbaum, G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0348 · Cited by 182
Self-citationChristen, U., McGavern, D. B., Luster, A. D., von Herrath, M. G., & Oldstone, M. B. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6838 · Cited by 178
Redjimi, N., Raffin, C., Raimbaud, I., Pignon, P., Matsuzaki, J., Odunsi, K. O., Valmori, D., & Ayyoub, M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0579 · Cited by 168
The Role of CXCR3 and Its Chemokine Ligands in Skin Disease and Cancer
Kuo, P. T., Zeng, Z., Salim, N., Mattarollo, S., Wells, J. W., & Leggatt, G. R. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00271 · Cited by 167
Zumwalt, T. J., Arnold, M., Goel, A., & Boland, C. R. (2014) · Oncotarget · doi:10.18632/oncotarget.3205 · Cited by 163
Li, C. X., Ling, C. C., Shao, Y., Xu, A., Li, X. C., Ng, K. T.-P., Liu, X. B., Ma, Y. Y., Qi, X., Liu, H., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.032 · Cited by 160
Chemokines and cancer: new immune checkpoints for cancer therapy
Karin, N. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.004 · Cited by 158
Self-citationLiu, L., Huang, D., Matsui, M., He, T. T., Hu, T., DeMartino, J. A., Lu, B., Gerard, C. J., & Ransohoff, R. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.7.4399 · Cited by 153
Sica, A., Saccani, A., Bottazzi, B., Bernasconi, S., Allavena, P., Gaetano, B., Fei, F., LaRosa, G., Scotton, C. J., Balkwill, F. R., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.2.733 · Cited by 153
Gangur, V., Estelle, F., Simons, R., & HayGlass, K. T. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.9.705 · Cited by 152
Lunardi, S., Jamieson, N. B., Lim, S. Y., Griffiths, K., Carvalho‐Gaspar, M., Al‐Assar, O., Yameen, S., Carter, R. C., McKay, C. J., Spoletini, G., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2519 · Cited by 149
Mulligan, A. M., Raitman, I., Feeley, L., Pinnaduwage, D., Nguyen, L. T., O’Malley, F. P., Ohashi, P. S., & Andrulis, I. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3314 · Cited by 143
Klein, R. S., Izikson, L., Means, T. K., Gibson, H. D., Lin, E., Sobel, R. A., Weiner, H. L., & Luster, A. D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.550 · Cited by 135
Targeting the Function of IFN-γ-Inducible Protein 10 Suppresses Ongoing Adjuvant Arthritis
Salomon, I., Netzer, N., Wildbaum, G., Schif‐Zuck, S., Maor, G., & Karin, N. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.5.2685 · Cited by 132
Self-citationYoussef, S., Wildbaum, G., Maor, G., Lanir, N., Gour-Lavie, A., Grabie, N., & Karin, N. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.8.3870 · Cited by 126
Self-citationAndrogen receptor gene mutations in hormone-refractory prostate cancer
Wall�n, M., Linja, M. J., Kaartinen, K., Schleutker, J., & Visakorpi, T. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199912)189:4<552::aid-path469>3.0.co;2-i · Cited by 115
Wildbaum, G., Netzer, N., & Karin, N. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5885 · Cited by 111
Self-citationFujita, M., Zhu, X., Ueda, R., Sasaki, K., Kohanbash, G., Kastenhuber, E. R., McDonald, H. A., Gibson, G. A., Watkins, S. C., Muthuswamy, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2915 · Cited by 108
Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes
Korniejewska, A., McKnight, A. J., Johnson, Z., Watson, M., & Ward, S. G. (2011) · Immunology · doi:10.1111/j.1365-2567.2010.03384.x · Cited by 102
Youssef, S., Maor, G., Wildbaum, G., Grabie, N., Gour-Lavie, A., & Karin, N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9109 · Cited by 101
Self-citationType I Interferon-Associated Recruitment of Cytotoxic Lymphocytes
Wenzel, J., Bekisch, B., Uerlich, M., Haller, O., Bieber, T. R. M., & Tüting, T. (2005) · American Journal of Clinical Pathology · doi:10.1309/4ej9-kl7c-gden-vvle · Cited by 99
Heparanase enhances myeloma progression via CXCL10 downregulation
Barash, U., Zohar, Y., Wildbaum, G., Beider, K., Nagler, A., Karin, N., Ilan, N., & Vlodavsky, I. (2014) · Leukemia · doi:10.1038/leu.2014.121 · Cited by 97
Self-citationBiased signaling pathways via CXCR3 control the development and function of CD4+ T cell subsets
Karin, N., Wildbaum, G., & Thelen, M. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.2mr0915-441r · Cited by 97
Self-citationCXCR3+ Regulatory T Cells Control TH1 Responses in Crescentic GN
Paust, H., Riedel, J.-H., Krebs, C. F., Turner, J., Brix, S. R., Krohn, S., Velden, J., Wiech, T., Kaffke, A., Peters, A., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015020203 · Cited by 94
Hawila, E., Razon, H., Wildbaum, G., Blattner, C., Sapir, Y., Shaked, Y., Umansky, V., & Karin, N. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.104 · Cited by 93
Self-citationTargeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers
Jacquelot, N., Duong, C. P. M., Belz, G. T., & Zitvogel, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02480 · Cited by 92
Doron, H., Amer, M., Ershaid, N., Blazquez, R., Shani, O., Lahav, T. G., Cohen, N., Adler, O., Hakim, Z., Pozzi, S., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.033 · Cited by 87
The CCL5/CCR5 axis promotes metastasis in basal breast cancer
Velasco-Velázquez, M. A., & Pestell, R. G. (2013) · OncoImmunology · doi:10.4161/onci.23660 · Cited by 80
Wildbaum, G., Nahir, M. A., & Karin, N. (2003) · Immunity · doi:10.1016/s1074-7613(03)00291-7 · Cited by 77
Self-citationCXCL10 expression and prognostic significance in stage II and III colorectal cancer
Jiang, Z., Xu, Y., & Cai, S. (2009) · Molecular Biology Reports · doi:10.1007/s11033-009-9873-z · Cited by 76
Effect of JAK Inhibitors on Release of CXCL9, CXCL10 and CXCL11 from Human Airway Epithelial Cells
Fenwick, P. S., Macedo, P., Kilty, I., Barnes, P. J., & Donnelly, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128757 · Cited by 73
Arenberg, D., White, E., Burdick, M., Strom, S., & Strieter, R. (2001) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-001-0231-9 · Cited by 73
Interferons Induce CXCR3-cognate Chemokine Production by Human Metastatic Melanoma
Dengel, L. T., Norrod, A. G., Gregory, B. L., Clancy‐Thompson, E., Burdick, M. D., Strieter, R. M., Slingluff, C. L., & Mullins, D. W. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181fb045d · Cited by 71
Wildbaum, G., Westermann, J., Maor, G., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8759 · Cited by 69
Bonanni, V., Antonangeli, F., Santoni, A., & Bernardini, G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0751-5 · Cited by 56
CXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivo
Antonicelli, F. D., Lorin, J., Kurdykowski, S., Gangloff, S. C., Naour, R. L., Sallenave, J., Hornebeck, W., Grange, F., & Bernard, P. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.10176.x · Cited by 54
Izhak, L., Wildbaum, G., Jung, S., Stein, A., Shaked, Y., & Karin, N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0028305 · Cited by 52
Self-citationNagpal, M. L., Davis, J., & Lin, T. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.06.017 · Cited by 51
Cytokines and Chemokines in the Pathogenesis of Experimental Autoimmune Encephalomyelitis
Karpus, W. J. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900914 · Cited by 51
Singh, U. P., Singh, S., Singh, R., Cong, Y., Taub, D. D., & Lillard, J. W. (2008) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2007.0059 · Cited by 49
CXCL10 mRNA expression predicts response to neoadjuvant chemoradiotherapy in rectal cancer patients
Li, C., Wang, Z., Liu, F., Zhu, J. Y., Li, Y., Cai, G., Zhang, Z., Huang, W. C., Cai, S., & Xu, Y. (2014) · Tumor Biology · doi:10.1007/s13277-014-2234-0 · Cited by 40
de Lange, M. J., Nell, R. J., Lalai, R. N., Versluis, M., Jordanova, E. S., Luyten, G. P. M., Jager, M. J., van der Burg, S. H., Zoutman, W. H., van Hall, T., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0114 · Cited by 40
Kim, J., Choi, J. Y., Park, S., Yang, S. H., Park, J. A., Shin, K., Lee, E., Kawachi, H., Kohsaka, H., & Song, Y. W. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4583 · Cited by 34
A novel prognostic model for osteosarcoma using circulating CXCL 10 and FLT 3 LG
Flores, R. J., Kelly, A. J., Li, Y., Nakka, M., Barkauskas, D. A., Krailo, M., Wang, L. L., Perlaky, L., Lau, C. C., Hicks, J. M., et al. (2016) · Cancer · doi:10.1002/cncr.30272 · Cited by 31
Chung, C., & Liao, F. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0536-4 · Cited by 26
Bolomsky, A., Schreder, M., Hübl, W., Zojer, N., Hilbe, W., & Ludwig, H. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2016.1151511 · Cited by 24
Dart, A. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2018.4 · Cited by 18
Zhang, J., Chen, J., Guan, G., Zhang, T., Lu, F., & Chen, X. M. (2019) · PubMed · doi:10.19723/j.issn.1671-167x.2019.03.005 · Cited by 18
Danovi, S. A. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.53 · Cited by 6
Cited by
The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment
Kim, S. K., & Cho, S. W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.868695 · Cited by 460
Vitanza, N. A., Johnson, A. J., Wilson, A. L., Brown, C., Yokoyama, J. K., Künkele, A., Chang, C. A., Rawlings-Rhea, S., Huang, W., Seidel, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01404-8 · Cited by 321
Metadata
- Authors
- Karin, N.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-05-29
- Volume
- 11
- Pages
- 976-976
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3032643111
- Cited by
- 278
- References
- 88
- FWCI
- 10.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.